San Diego – September 21, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that it will present results from three studies featuring its Decipher® Prostate and Bladder Cancer Classifier Tests and Decipher Genomics Resource Information Database (Decipher GRID®) at the American Society for Radiation Oncology (ASTRO) Annual Meeting being held September 24-27 in San Diego, California.
Title: Novel Associations Between the Immune Landscape of Prostate Cancer and Postoperative Radiation Response
Presentation Number: 3
Date and Time: Sunday, Sept. 24 — 3:15 p.m. to 4:45 p.m. (PDT)
Room: Ballroom 20
Session: Clinical Trials Session CT01
Presenter: Shuang George Zhao, M.D., MSE, University of Michigan
Title: Development and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk
Presentation Number: 210
Date and Time: Tuesday, Sept. 26 — 2:45 p.m. to 4:15 p.m. (PDT)
Room: Room 3
Session: GU 1: Genomics, Imaging and Salvage Local Therapies after Prostatectomy or Post-Radiotherapy Relapse SS28
Presenter: Daniel Spratt, M.D., University of Michigan
Title: Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality Therapy
Presentation Number: 254
Date and Time: Wednesday, Sept. 27 — 7:45 a.m. to 9:00 a.m. (PDT)
Room: Room 30 D/E
Session: GU 2: Emerging Data on Bladder Preservation SS34
Presenter: Jason Efstathiou, M.D., Ph.D., Massachusetts General Hospital
About Decipher Cancer Classifier Tests and GRID®
GenomeDx’s Decipher prostate and bladder cancer classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment.
The Decipher tests are derived from GenomeDx’s Decipher Genomics Resource Information Database (GRID). GRID contains the genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genetic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
About GenomeDx Biosciences
GenomeDx is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. GenomeDx is headquartered in Vancouver, British Columbia, and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com